CD19 and myeloid sarcoma: Finally, we sought to evaluate the cytolytic ability and activation of CABA-201 generated from the T cells of patients with autoimmune disease (mcPV, SLE, MS, RA, SSc, and IIM) toward the intended target CD19+ B cells isolated from the same patients.